Literature DB >> 21198433

High mobility group box protein-1 in HIV-1 infection.

Marius Trøseid1, Anders Sönnerborg, Piotr Nowak.   

Abstract

Chronic immune activation driven by microbial translocation from a damaged gut plays a fundamental role in HIV-1 progression. However, the exact link between a leaky gut and immune activation remains to be established. A growing body of evidence suggests that high mobility group box protein-1 (HMGB1) may be involved in this process. HMGB1 is a DNA binding protein present in every nucleated cell, which might be actively secreted to the extracellular milieu by activated cells or passively released from damaged or dying cells. The biological effect depends on its ability to form complexes: HMGB1 alone signals through the receptor of advanced glycosylated end products (RAGE) and promotes regeneration and repair, whereas HMGB1 in complex with bacterial products signal via toll like receptors (TLRs) and promotes immune activation. Plasma levels of HMGB1 are elevated in HIV-1 infected patients and reduced by antiretroviral therapy. The protein might be released from necrotic and apoptotic HIV-1 infected cells. HMGB1 may stimulate or inhibit HIV-1 replication in vitro, depending on the stage of infection, type of cell and purity of the protein: The protein has been suggested to reduce viral replication by interfering with viral entry in acute infection and to increase viral replication in latently infected cells. Finally, HMGB1 in combination with microbial products/TLR ligands seems to be associated with increased viral replication in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21198433     DOI: 10.2174/157016211794582632

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  10 in total

1.  Short Communication: Effect of Antiretroviral Therapy on Circulating Damage-Associated Molecular Pattern Molecules and CD4 Immune Reconstitution in HIV-Infected Individuals.

Authors:  Daniel R Drozd; Susan M Graham; Heidi M Crane; Joseph A C Delaney; Mari M Kitahata; Wayne Conrad Liles
Journal:  AIDS Res Hum Retroviruses       Date:  2016-06-13       Impact factor: 2.205

2.  Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA.

Authors:  Elena S Kim; Jun Zhou; Hu Zhang; Alexander Marchetti; Maarten van de Klundert; Dawei Cai; Xiaoyang Yu; Bidisha Mitra; Yuanjie Liu; Mu Wang; Ulrike Protzer; Haitao Guo
Journal:  PLoS Pathog       Date:  2022-06-09       Impact factor: 7.464

Review 3.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities.

Authors:  Netanya G Sandler; Daniel C Douek
Journal:  Nat Rev Microbiol       Date:  2012-08-13       Impact factor: 60.633

Review 4.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

5.  Impact of HMGB1/TLR Ligand Complexes on HIV-1 Replication: Possible Role for Flagellin during HIV-1 Infection.

Authors:  Piotr Nowak; Samir Abdurahman; Annica Lindkvist; Marius Troseid; Anders Sönnerborg
Journal:  Int J Microbiol       Date:  2012-06-06

6.  The Initial Months of Antiretroviral Therapy and Its Influence on AGEs, HMGB1, and sRAGE Levels in Asymptomatic HIV-Infected Individuals.

Authors:  Karen Ingrid Tasca; Juliana Trindade Caleffi; Camila Renata Correa; Mariana Gatto; Caio Cavassan de Camargo; Monica Bannwart Mendes; Marjorie de Assis Golim; Mara Biasin; Lenice do Rosário de Souza
Journal:  Mediators Inflamm       Date:  2016-11-30       Impact factor: 4.711

7.  Alteration of serum high-mobility group protein 1 (HMGB1) levels in children with enterovirus 71-induced hand, foot, and mouth disease.

Authors:  Weikun Zheng; Haifan Shi; Yiping Chen; Zhiwei Xu; Jie Chen; Longteng Jin
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

8.  Serum vitamin D receptor and High Mobility Group Box-1 (HMGB1) levels in HIV-infected patients with different immunodeficiency status: A cross-sectional study.

Authors:  Indah Sapta Wardani; Mochammad Hatta; Risna Halim Mubin; Agussalim Bukhari; Muhammad Nasrum Massi; Irawaty Djaharuddin; Burhanuddin Bahar; Siti Wahyuni
Journal:  Ann Med Surg (Lond)       Date:  2021-02-12

Review 9.  Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates.

Authors:  Sajad Fakhri; Zeinab Nouri; Seyed Zachariah Moradi; Esra Küpeli Akkol; Sana Piri; Eduardo Sobarzo-Sánchez; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

10.  Asymptomatic HIV People Present Different Profiles of sCD14, sRAGE, DNA Damage, and Vitamins, according to the Use of cART and CD4+ T Cell Restoration.

Authors:  Karen Ingrid Tasca; Camila Renata Correa; Juliana Trindade Caleffi; Monica Banwart Mendes; Mariana Gatto; Vanessa Martinez Manfio; Caio Cavassan de Camargo; Francilene Capel Tavares; Mara Biasin; Lenice do Rosário de Souza
Journal:  J Immunol Res       Date:  2018-04-10       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.